Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Orphazyme A/S	ORIC Pharmaceuticals	Chimerix	Calliditas Therapeutics AB (publ)	Sesen Bio
Symbol	NASDAQ:ORPH	NASDAQ:ORIC	NASDAQ:CMRX	NASDAQ:CALT	NASDAQ:SESN
Price Information
Current Price	$6.52	$18.90	$8.20	$28.00	$4.17
52 Week Range	Sell	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	0.8	1.6	1.7	1.3	1.3
Analysis Score	2.7	3.3	4.5	3.5	3.5
Community Score	1.4	2.9	2.4	2.6	2.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	1.7	0.8	0.0	0.0
Earnings & Valuation Score	0.0	0.0	0.6	0.6	0.6
Analyst Ratings
Consensus Recommendation	Sell	Buy	Buy	Buy	Buy
Consensus Price Target	$16.00	$44.33	$19.00	$40.80	$7.50
% Upside from Price Target	145.40% upside	134.57% upside	131.71% upside	45.71% upside	79.86% upside
Trade Information
Market Cap	$227.89 million	$693.55 million	$706.93 million	$699.19 million	$722.61 million
Beta	N/A	2.81	1.59	N/A	0.82
Average Volume	3,966,042	244,033	983,466	33,455	6,522,474
Sales & Book Value
Annual Revenue	N/A	N/A	$5.37 million	$90,000.00	$11.24 million
Price / Sales	N/A	N/A	131.64	7,768.76	64.29
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$2.74 per share	$9.40 per share	$1.17 per share	$5.71 per share	($0.07) per share
Price / Book	N/A	N/A	7.01	4.90	-59.57
Profitability
Net Income	$-97,010,000.00	$-73,700,000.00	$-43,520,000.00	$-47,250,000.00	$-22,400,000.00
EPS	($3.42)	($3.36)	($0.70)	($2.11)	($0.15)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	29.79
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	-2,344.90%	N/A	N/A
Return on Equity (ROE)	N/A	-34.41%	-49.70%	-39.44%	N/A
Return on Assets (ROA)	N/A	-33.33%	-43.44%	-35.09%	-87.65%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.05%	N/A	N/A	N/A	N/A
Current Ratio	4.70%	36.49%	6.66%	7.75%	7.29%
Quick Ratio	4.70%	36.49%	6.66%	7.75%	7.29%
Ownership Information
Institutional Ownership Percentage	0.83%	97.25%	55.88%	9.35%	23.14%
Insider Ownership Percentage	N/A	N/A	9.00%	N/A	2.20%
Miscellaneous
Employees	141	61	54	34	27
Shares Outstanding	34.95 million	36.70 million	86.21 million	24.97 million	173.29 million
Next Earnings Date	N/A	8/4/2021 (Estimated)	8/9/2021 (Estimated)	8/12/2021 (Estimated)	8/9/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Should This Make Sesen Bio Inc. (NASDAQ: SESN) Investors Sleepless At Night? stocksregister.com - June 21 at 8:45 AM
	Sesen Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) \| Morningstar morningstar.com - June 20 at 12:43 AM
	Sesen Bio, Inc. (NASDAQ:SESN) Has Recovered 85.29% So Far, But Another 4% Gain Cannot Be Ruled Out marketingsentinel.com - June 18 at 12:57 PM
	Sesen Bio (NASDAQ:SESN) Trading Up 8.5% americanbankingnews.com - June 17 at 12:19 PM
	A Look At Sesen Bio Inc. (SESN) Stock Performance stocksregister.com - June 17 at 10:04 AM
	Sesen Bio Inc. [SESN] Revenue clocked in at $15.50 million, up 211.11% YTD: What’s Next? dbtnews.com - June 16 at 6:16 PM
	Sesen Bio (NASDAQ:SESN) Is In A Strong Position To Grow Its Business finance.yahoo.com - June 15 at 2:49 PM
	Sesen Bio Inc. (SESN) Has Great Growth Outlook For 2021 marketingsentinel.com - June 15 at 9:25 AM
	Sesen Bio (NASDAQ:SESN) Reaches New 12-Month High at $4.36 americanbankingnews.com - June 14 at 11:02 AM
	Is Now The Right Time To Buy Sesen Bio Inc. (NASDAQ: SESN) Stock? stocksregister.com - June 14 at 8:45 AM
	Sesen Bio Inc. (NASDAQ: SESN) Continues To Thrive In 2021, As Its Stock Is Up 209.63% Year-To-Date marketingsentinel.com - June 11 at 7:31 AM
	Sesen Bio Inc. (NASDAQ: SESN)’s Upside Potential Is High stocksregister.com - June 10 at 9:52 AM
	Sesen Bio (NASDAQ:SESN) Reaches New 52-Week High at $3.97 americanbankingnews.com - June 7 at 1:20 PM
	Sesen Bio, Inc. (NASDAQ:SESN)’s stock boosts 1.35%, but it may be a worthy investment stocksregister.com - June 7 at 12:21 PM
	Sesen Bio, Inc. (NASDAQ:SESN) Have Surged 174.07% YTD, Predicting what happens next in marketingsentinel.com - June 4 at 1:58 PM
	Analysts Recommend Holding Your Position In Sesen Bio Inc. (NASDAQ: SESN) stocksregister.com - June 2 at 12:59 PM
	Sesen Bio (NASDAQ:SESN) Shares Gap Down to $3.87 americanbankingnews.com - June 2 at 10:55 AM
	Sesen Bio, Inc. (NASDAQ:SESN) Stock Forecast for 2021: Bullish Signs Point to $8 per Share marketingsentinel.com - June 1 at 2:09 PM
	Sesen Bio (NASDAQ:SESN) Reaches New 1-Year High at $3.60 americanbankingnews.com - June 1 at 1:40 PM
	Sesen Bio Strengthens Senior Leadership Team finance.yahoo.com - June 1 at 8:18 AM
	Market Analysts see Sesen Bio Inc. [SESN] gaining to $3. Time to buy? dbtnews.com - May 31 at 2:05 PM
	Sesen Bio, Inc. (NASDAQ:SESN) Sees Significant Growth in Short Interest americanbankingnews.com - May 30 at 3:40 AM
	Sesen Bio (NASDAQ:SESN) Sees Unusually-High Trading Volume americanbankingnews.com - May 28 at 10:50 AM
	Sesen Bio, Inc. (NASDAQ:SESN) Stock You Missed During the Week stocksregister.com - May 27 at 5:29 PM
	Sesen Bio, Inc. (NASDAQ:SESN) Has Recovered 77.56% So Far, But Another 21.02% Gain Cannot Be Ruled Out marketingsentinel.com - May 27 at 12:29 PM

Date	Company	Brokerage	Action
6/21/2021	Orphazyme A/S	Guggenheim	Downgrade
6/18/2021	Orphazyme A/S	Cowen	Downgrade
3/30/2021	Orphazyme A/S	Bank of America	Downgrade
6/6/2021	ORIC Pharmaceuticals	Robert W. Baird	Reiterated Rating
3/25/2021	ORIC Pharmaceuticals	HC Wainwright	Boost Price Target
1/25/2021	ORIC Pharmaceuticals	Citigroup	Downgrade
6/19/2020	ORIC Pharmaceuticals	Oppenheimer	Reiterated Rating
5/19/2020	ORIC Pharmaceuticals	JPMorgan Chase & Co.	Initiated Coverage
5/19/2020	ORIC Pharmaceuticals	Jefferies Financial Group	Initiated Coverage
4/29/2021	Chimerix	Maxim Group	Initiated Coverage
4/12/2021	Chimerix	Jonestrading	Reiterated Rating
3/31/2021	Chimerix	Wedbush	Initiated Coverage
8/18/2020	Calliditas Therapeutics AB (publ)	Ci Capital	Reiterated Rating
6/30/2020	Calliditas Therapeutics AB (publ)	Stifel Nicolaus	Initiated Coverage
3/16/2021	Sesen Bio	Canaccord Genuity	Reiterated Rating
8/9/2019	Sesen Bio	Laidlaw	Downgrade

(Data available from 6/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources